Sandoz Group AG (SWX:SDZ)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 30.05B +67.0% |
| Revenue (ttm) | 8.85B +7.4% |
| Net Income | 724.76M |
| EPS | 1.66 |
| Shares Out | 432.69M |
| PE Ratio | 41.90 |
| Forward PE | 20.88 |
| Dividend | 0.80 (1.18%) |
| Ex-Dividend Date | Apr 13, 2026 |
| Volume | 272,087 |
| Open | 69.00 |
| Previous Close | 67.92 |
| Day's Range | 68.06 - 69.44 |
| 52-Week Range | 42.01 - 72.70 |
| Beta | 0.53 |
| Analysts | Buy |
| Price Target | 71.13 (+2.43%) |
| Earnings Date | Aug 5, 2026 |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]
Full Company ProfileAnalyst Summary
According to 15 analysts, the average rating for SDZ stock is "Buy." The 12-month stock price target is CHF 71.13, which is an increase of 2.43% from the latest price.
News
Generic drugmaker Sandoz files anti-dumping complaint about Chinese antibiotics imports
Swiss generic drugmaker Sandoz filed a draft anti-dumping complaint with the European Commission over Chinese imports of the antibiotic ingredient amoxicillin, part of the penicillin family, the co...
Sandoz CEO Says Size of Weight-Loss Generics Market Is Unknown
Switzerland's Sandoz sees Canada and Brazil markets as testing grounds before semaglutide goes off patent in Europe and the U.S. in the 2030s.
Sandoz Group AG Earnings Call Transcript: Q1 2026
Q1 2026 saw robust biosimilar-driven growth, with net sales up 11% headline and 3% at constant currency, and biosimilars now 31% of sales. Generics faced headwinds but are expected to stabilize, while full-year guidance for mid to high single-digit growth and margin expansion is confirmed.
Sandoz Group AG Slides: Q1 2026
Sandoz Group AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
Sandoz Group AG Earnings release: Q1 2026
Sandoz Group AG released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
Sandoz Shares Jump on Improved Guidance
Stock rose 6.4% after the company bumped up its revenue guidance thanks to growth in its biosimilar product range.
Sandoz Group AG Earnings Call Transcript: Q4 2025
Net sales grew 5% to $11.1B in 2025, with biosimilars now 30% of sales and core EBITDA margin up to 21.7%. Strong launches, strategic acquisitions, and robust pipeline support mid to high single-digit sales growth in 2026, despite ongoing generics pricing pressures.
Sandoz Group AG Earnings release: Q4 2025
Sandoz Group AG released its Q4 2025 earnings on February 25, 2026, summarizing the period's financial results.
Sandoz Group AG Annual report: Q4 2025
Sandoz Group AG has published its Q4 2025 annual report on February 25, 2026.
Sandoz Group AG Slides: Q4 2025
Sandoz Group AG has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 25, 2026.
Sandoz Group AG Transcript: 44th Annual J.P. Morgan Healthcare Conference
The session highlighted a strong focus on biosimilars and generics, with robust financials, a leading global pipeline, and major investments in manufacturing and innovation. Strategic launches, regulatory tailwinds, and a shift toward biologics position the company for accelerated growth beyond 2028.
Sandoz Group AG Slides: 44th Annual J.P. Morgan Healthcare Conference
Sandoz Group AG has posted slides in relation to its latest quarterly earnings report, which was published on January 13, 2026.
Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz
All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in November Agreement includes approximately US$ 350 m in cash for Just ...
Sandoz Group AG Transcript: Jefferies London Healthcare Conference 2025
The session highlighted a conservative approach to GLP-1 expansion, a strong focus on biosimilars with multiple launches, and strategic acquisitions to enhance control and flexibility. Financial guidance remains on track, with operational efficiency and pipeline growth prioritized.
Sandoz CEO expects Ozempic biosimilars to enter Canadian market in Q1, Q2
Generic drug giant Sandoz expects unbranded versions of Novo Nordisk's popular diabetes drug Ozempic to launch in Canada by the second quarter next year after a key patent expires, its CEO said on Wed...
EirGenix Signed The Commercial Licensinse Agreement for It's Second HER2 Biosimilar Asset EG1206A
TAIPEI , Nov. 12, 2025 /PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (...
Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities
Group revenues of € 535.1 m ((7.1)%); Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand;Just - Evotec Biologics ("JEB"; +11.3%) above-expectation; further accelerati...
In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties
Transaction showcases Evotec's unique capability enabling customers to produce biologics faster and at lower costs through its continuous manufacturing technology Accelerated implementation of strateg...
Drugmakers must face skincare drug price-fixing lawsuit, US judge rules
A federal judge on Friday said 36 drugmakers and executives must face nearly all claims in an antitrust lawsuit brought by most U.S. states, accusing them of conspiring to fix prices of 80 generic dru...
Sandoz Group AG Earnings Call Transcript: Q3 2025
Delivered 5% net sales growth and upgraded core EBITDA margin guidance to 21%-22%, driven by strong biosimilar launches and commercial execution. Biosimilars now represent a record 31% of net sales, with further launches and pipeline expansion supporting sustained growth.
Sandoz Group AG Earnings release: Q3 2025
Sandoz Group AG released its Q3 2025 earnings on October 30, 2025, summarizing the period's financial results.
Sandoz Group AG Slides: Q3 2025
Sandoz Group AG has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 30, 2025.
Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US
PRINCETON, N.J.--(BUSINESS WIRE)--Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent appro...
Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
MEDIA RELEASE Sandoz signs 10-year virtual PPA with Elawan Energy for new 150 MW solar projects in Spain Will cover nearly 90% of electricity demand for European operations Concrete step to support gl...
Sandoz Group AG Earnings Call Transcript: Q2 2025
Delivered strong H1 2025 results with 6% underlying sales growth, 2.5pp EBITDA margin expansion, and biosimilars reaching 30% of Q2 net sales. Confirmed full-year guidance, expanded manufacturing, and announced a $300M biosimilar acquisition.